Tigecycline in the Treatment of Patients with Necrotizing Skin and Soft Tissue Infections Due to Multiresistant Bacteria

Surgical Infections

Volumn 16, Issue 5, 2015, Pages 618-625

  Eckmann, Christian ^a   Heizmann, Wolfgang ^b   Bodmann, Klaus Friedrich ^c   Von Eiff, Christoph ^d   Petrik, Christian ^d   Loeschmann, Peter Andreas ^d  

^a Department of General   (Germany)

^b Center of Microbiology and Infectiology   (Germany)

^c Werner Forßmann Hospital   (Germany)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEM; CARBAPENEM DERIVATIVE; CEPHALOSPORIN; CEPHALOSPORIN DERIVATIVE; GLYCOPEPTIDE; IMIDAZOLE DERIVATIVE; LINCOSAMIDE; NITROIMIDAZOLE; PENICILLIN DERIVATIVE; QUINOLONE DERIVATIVE; TIGECYCLINE; TRIAZOLE; ANTIINFECTIVE AGENT; MINOCYCLINE;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; APACHE; ARTICLE; CHILL; CLINICAL PRACTICE; CONTROLLED STUDY; DEBRIDEMENT; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENTEROBACTERIACEAE; ENTEROCOCCUS; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; FEMALE; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; SEPSIS; SKIN NECROSIS; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; VANCOMYCIN RESISTANT ENTEROCOCCUS; VERY ELDERLY; ANALOGS AND DERIVATIVES; ANIMAL; BACTERIAL INFECTIONS; BACTERIUM; CLINICAL TRIAL; CRITICAL ILLNESS; DRUG EFFECTS; ISOLATION AND PURIFICATION; MULTIDRUG RESISTANCE; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; CRITICAL ILLNESS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MINOCYCLINE; PROSPECTIVE STUDIES; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84943805119     PISSN: 10962964     EISSN: 15578674     Source Type: Journal    
DOI: 10.1089/sur.2014.089     Document Type: Article

References (21)

1. DiNubile MJ, Lipsky BA. Complicated infections of skin and skin structures: When the infections is more than skin deep. J Antimicrob Chemother 2004;53:37-50.
2. U. S. Centers for Disease Control. Incidence of soft tissue infections: San Francisco General Hospital 1996-2000. MMWR Morb Wkly Rep 2001; 50:381-384.
3. Nichols RL, Florman S. Clinical presentation of soft tissue infections and surgical site infections. Clin Inf Dis 2001; 33:S83-93.
4. Lipsky BA. Cellulitis, erysipelas and necrotizing soft tissue infections. Best Practice of Medicine 2002. www . bestpracticeofmedicine. com.
5. Engel C, Brunkhorst FM, Bone HG, et al. Epidemiology of sepsis in Germany: Results from a national prospective multicenter study. Intensive Care Med 2007;33:606-618.
6. Center for Drug Evaluation and Research (CDER). Uncomplicated and complicated skin and skin-structure infections-developing antimicrobial drugs for treatment. 1998. www. fda. gov/ cder/guidance/2566dft. pdf
7. Kingston D, Seal DV. Current hypotheses for synergistic microbial gangrene. Br J Surg 1990;77:260.
8. Jones ME, Karlowsky JA, Draghi DC, et al. Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: A guide to appropriate antimicrobial therapy. Int J Antimicrob Agents 2003; 22:406-19.
9. Giordano P, Song J, Pertel P, et al. Sequential intravenous/ oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection. Int J Antimicrob Agents 2005;2:357-365.
10. Moet GJ, Jones RN, Biedenbach DJ, et al. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: Report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Diagn Microbiol Infect Dis 2007;57:7-13.
11. Tsitsilonis S, Druschel C, Wichlas F, et al. Necrotizing fasciitis: Is the bacterial spectrum changing? Langenbecks Arch Surg 2013;398:153-159.
12. Ellis-Grosse EJ, Babinchak T, Dartois N, et al. The efficacy and safety of tigecycline in the treatment of skin and skinstructure infections: Results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005;41:S341-S353.
13. Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skinstructure infections. Clin Infect Dis 2004;38:1673-1681.
14. Wilson SE, O'Riordan W, Hopkins A, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections associated with surgical procedures. Am J Surg 2009;197:791-796.
15. Bodmann KF, Heizmann WR, von Eiff C, et al. Therapy of 1,025 severely ill patients with complicated infections in a German multicenter study: Safety profile and efficacy of tigecycline in different treatment modalities. Chemotherapy 2012;58:282-294.
16. Kujath P, Eckmann C, Benecke P. Diagnose und Therapie der nekrotisierenden Fasziitis. Deutsch Med Wochenschr 1995;120:965-968.
17. Tygacil (tigecycline) summary of product characteristics. EMA 2013.
18. Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013;39:165-228.
19. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006;34:1589-1596.
20. Chao WN, Tsai CF, Chang HR, et al. Impact of timing of surgery on outcome of Vibrio vulnificus-related necrotizing fasciitis. Am J Surg 2013;206:32-39.
21. Psoinos CM, Flahive JM, Shaw JJ, et al. Contemporary trends in necrotizing soft tissue infections in the United States. Surgery 2013;153:819-827.